The potential of oncolytic adenoviral vectors

admin_vjr_user — Mon, 16 Aug 2021 08:50:48 +0000

Margarita Romanenko, PhD, University of Minnesota, Minneapolis, MN, discusses potential future applications of oncolytic adenoviral vectors. Currently approved vector-based COVID-19 vaccines utilize adenoviral vector technology of varying serotypes, including adenovirus serotype 6 (Ad6). Dr Romanenko anticipates that therapeutics based on a range of adenovirus serotypes will be developed in the future and highlights this technology’s promise given the oncolytic potential and capacity for gene insertion associated with oncolytic adenoviral vectors. This interview took place during the American Society for Cell & Gene Therapy 24th Annual Meeting 2021.

Novel oncolytic Ad6 vectors for cancer therapy

admin_vjr_user — Thu, 03 Jun 2021 16:50:51 +0000

Margarita Romanenko, PhD, University of Minnesota, Minneapolis, MN, describes a novel adenovirus serotype 6 (Ad6) oncolytic vector currently being investigated for the potential treatment of different cancer types such as glioblastoma and breast cancer. With the aim of enhancing anti-tumor efficacy, a recombinant Ad6 vector was developed with the tumor-specific human telomerase reverse transcriptase (hTERT) promoter and the expression of the human granulocyte macrophage colony-stimulating factor (GMCSF). Further preclinical study is required to further evaluate the potential of the Ad6-hTERT-GMCSF vector as an oncolytic vector and a vaccine. This interview took place during the American Society for Cell & Gene Therapy 24th Annual Meeting 2021.

Margarita Romanenko – VJRegenMed

The potential of oncolytic adenoviral vectors

Novel oncolytic Ad6 vectors for cancer therapy